ASCO: Obesity and ER+ breast cancer mortality link limited to pre-menopause

Share this content:
ASCO: Obesity, Mortality Link in ER+ Breast CA Pre-Menopause
ASCO: Obesity, Mortality Link in ER+ Breast CA Pre-Menopause

(HealthDay News) -- In estrogen receptor (ER)+ breast cancer, obesity is positively associated with breast cancer mortality only among pre-/peri-menopausal women, according to new research. These findings have been released in advance of presentation at the annual meeting of the American Society of Clinical Oncology, to be held from May 30 to June 3 in Chicago.

Hongchao Pan, Ph.D., from the University of Oxford in the United Kingdom, and colleagues used data from the Early Breast Cancer Trialists' Collaborative Group study to analyze the independent effects of body mass index (BMI) on outcome. Data were included for 80,000 patients in 70 trials, with mean follow-up of eight women-years.

The researchers observed little correlation between BMI and breast cancer mortality for 20,000 women with ER+ disease, and the association no longer persisted after adjustment for tumor diameter and nodal status. BMI correlated positively with breast cancer mortality in 60,000 women with ER+ disease, including women who were pre-, peri-, and post-menopause. After adjustment for tumor characteristics, the correlation persisted only for the 20,000 pre-/peri-menopausal women with ER+ disease (breast cancer mortality rate ratio for BMI ≥30 versus 20 to 25 kg/m², 1.34; P < 0.00001). For the 40,000 post-menopausal women with ER+ disease, little association persisted (rate ratio, 1.6; P = 0.12).

"This means we don't understand the main biological mechanisms by which obesity affects prognosis," Pan said in a statement.

Press Release
More Information

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs